News
PURPOSECannabis has been legalized across multiple states over the past decade; however, its use among cancer survivors ...
Venous thromboembolic events are commonly either under-reported or underestimated in clinical trials where the primary goal is to evaluate the effectiveness of anticancer therapies (Table 1). 8, 12 - ...
Effective treatment options, such as resection, liver transplantation, and ablation, exist for early-stage HCC, and patients with locally advanced disease may be candidates for liver-directed ...
Background: Anti-PD- (L) 1 monotherapy has been the standard first-line treatment for PD-L1 positive NSCLC, but its clinical benefit remains unsatisfactory. Benmelstobart (TQB2450) is a humanized ...
Patients with suspected stage III-IV EOC should be evaluated by a gynecologic oncologist, with cancer antigen 125, computed tomography of the abdomen and pelvis, and chest imaging included. All ...
Neuroendocrine neoplasms (NENs) include poorly differentiated neuroendocrine carcinomas, well-differentiated neuroendocrine tumors (NETs), and mixed neuroendocrine non-NENs. 1 The focus of this ...
Clinical Practice Guidelines and other guidance (“Guidance”) provided by ASCO is not a comprehensive or definitive guide to treatment options. It is intended for voluntary use by clinicians and should ...
Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors plus endocrine therapy (ET) represents the standard first-line treatment for patients with hormone receptor–positive/human epidermal growth factor ...
Not surprisingly, women receiving the CDK4/6 inhibitors in the adjuvant setting had an increased probability of nausea, hair thinning, hepatic function abnormalities, fatigue, infection risk, and ...
A systematic review by a multidisciplinary panel with patient representation was conducted. The PubMed database was searched from January 2018 to May 2024. Articles were selected for inclusion if they ...
This investigator-sponsored, multicenter, phase II study enrolled patients with treatment-naïve CLL enriched for high-risk CLL, defined by TP53 aberration (ClinicalTrials.gov identifier: NCT03580928).
Evidence-based recommendations address the integration of palliative care in oncology. Oncology clinicians should refer patients with advanced solid tumors and hematologic malignancies to specialized ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results